Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...

Traditional drug development methods involve identifying a target protin (e.g., a cancer cell receptor) that causes disease, and then searching through countless molecular candidates (potential drugs) ...

In recent years, target-based drug discovery has undergone a renaissance thanks to polypharmacology. In contrast to the conventional lock-and-key or one target-one drug model of drug design, ...

Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

For years, a protein inside our cells has quietly powered billions of dollars' worth of cancer drugs. Now a team of researchers have discovered that this workhorse protein, called cereblon, in ...

Artificial intelligence (AI) deep learning is rapidly transforming the biotechnology and pharmaceutical industries. New AI models based on ChatGPT-like algorithms are emerging in many industry ...

Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...

CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...